ライフサイエンスコーパス: treatment outcome

1 clinical and demographic characteristics and treatment outcome.

2 ng modalities may hold promise in predicting treatment outcome.

3 results, and clinical variables to tSCC and treatment outcome.

4 y reduced in all participants, regardless of treatment outcome.

5 mechanisms of tumor growth, resistance, and treatment outcome.

6 nfection (PAD) could support the periodontal treatment outcome.

7 fraction in the prediction of the radiation treatment outcome.

8 f the use of genetic risk factors to predict treatment outcome.

9 f metformin before radiotherapy on long-term treatment outcome.

10 on and nuclear membrane modifications on the treatment outcome.

11 her doses of PEG-asparaginase did not affect treatment outcome.

12 r factors influencing cancer progression and treatment outcome.

13 in 104/646 (16%) patients with no effect on treatment outcome.

14 e significantly associated with unsuccessful treatment outcome.

15 ges of care required to achieve a successful treatment outcome.

16 ology or have any significant effect on rCDI treatment outcome.

17 nd IgG(4) binding to epitopes, regardless of treatment outcome.

18 ately facilitate a more predictable, optimal treatment outcome.

19 ict 2-month culture conversion and long-term treatment outcome.

20 issue homeostasis, tumorigenesis, and cancer treatment outcome.

21 e a proper predictor of clinically favorable treatment outcome.

22 rphisms rs13900(C/T) and rs2857656(G/C) with treatment outcome.

23 repetitive transcranial magnetic stimulation treatment outcome.

24 odontic space closure and may compromise the treatment outcome.

25 DST and MIC for PZA were not associated with treatment outcome.

26 ne levels are associated with antidepressant treatment outcome.

27 tated primary cells, explaining the improved treatment outcome.

28 ymes poses a detriment to patient safety and treatment outcome.

29 tiretroviral therapy adherence and have poor treatment outcomes.

30 nt negative impact on periodontal health and treatment outcomes.

31 to improve the current marginally effective treatment outcomes.

32 on within a tumor is a determinant of better treatment outcomes.

33 ns between lifestyle factors and infertility treatment outcomes.

34 sess suppression over time and predictors of treatment outcomes.

35 r (TNF) treatment has significantly improved treatment outcomes.

36 ased adherence to therapy plans and improved treatment outcomes.

37 vant indicators of recovery or for assessing treatment outcomes.

38 l questions, from diagnosis to prediction of treatment outcomes.

39 tment can potentially be improved to improve treatment outcomes.

40 d it is not clear how it affects interim and treatment outcomes.

41 pathomechanisms, clinical heterogeneity and treatment outcomes.

42 is (DUP) predicts illness severity and worse treatment outcomes.

43 h reported COVID-19 clinical features and/or treatment outcomes.

44 IDSA guidelines and published literature on treatment outcomes.

45 ent drug-related side effects and suboptimal treatment outcomes.

46 lts were retrospectively compared to patient treatment outcomes.

47 ce of potentially influential factors on the treatment outcomes.

48 es and will have a significant impact on the treatment outcomes.

49 n, determine disease severity, and determine treatment outcomes.

50 predictive value of this novel biomarker on treatment outcomes.

51 anticancer therapeutic delivery with better treatment outcomes.

52 ir respective impact on disease severity and treatment outcomes.

53 lication protocols that might lead to better treatment outcomes.

54 are incompletely understood, leading to poor treatment outcomes.

55 tigated further in a phase 3 trial assessing treatment outcomes.

56 od to reduce onward transmission and improve treatment outcomes.

57 pe clinical data to shed light on individual treatment outcomes.

58 ystem and identified factors associated with treatment outcomes.

59 hemotherapeutic compounds and improve cancer treatment outcomes.

60 for pulmonary tuberculosis (TB) and adverse treatment outcomes.

61 atient response rates and lead to successful treatment outcomes.

62 rmed to validate metabolites associated with treatment outcomes.

63 on the hepatitic C virus (HCV) has improved treatment outcomes.

64 s with respect to immunotherapeutic or other treatment outcomes.

65 p disturbances, which are predictive of poor treatment outcomes.

66 of complex microbial communities to improve treatment outcomes.

67 macodynamics, safety of off-label doses, and treatment outcomes.

68 s have assessed whether they can improve HIV treatment outcomes.

69 ular age-related macular degeneration (nAMD) treatment outcomes.

70 o arousal have considerable implications for treatment outcomes.

71 e, and tuberculosis incidence, severity, and treatment outcomes.

72 ble health policy intervention to improve TB treatment outcomes.

73 formed decisions and optimize dental implant treatment outcomes.

74 ion of specific cortices can improve aphasia treatment outcomes.

75 stric bypass (RYGB) with respect to diabetes treatment outcomes.

76 people with HIV is associated with poor HIV treatment outcomes.

77 odel with results from a Markov model of HCV treatment outcomes.

78 ensitive TB diagnostics tests, and improving treatment outcomes.

79 ypic drug susceptibility testing can improve treatment outcomes.

80 ision making in addiction, thereby improving treatment outcomes.

81 tributable fraction of tuberculosis and poor treatment outcomes.

82 l consequences of HSCTlite and its impact on treatment outcomes.

83 aluate the effect of the BFP on tuberculosis treatment outcomes.

84 mise in being used in the future to evaluate treatment outcomes.

85 scarce access to viral load tests to monitor treatment outcomes.

86 d plasma cell leukemia, correlating to worse treatment outcomes.

87 ed drug regimens and may lead to improved TB treatment outcomes.

88 risk factors typically associated with poor treatment outcomes.

89 and further refinement is needed to improve treatment outcomes.

90 has great potential to improve long-term HIV treatment outcomes.

91 s therefore crucial for correctly predicting treatment outcomes.

92 ith isoniazid resistance and tSCC or initial treatment outcomes.

93 diagnosis system, and a prediction model for treatment outcomes.

94 or toxicological assays to accurately report treatment outcomes.

95 ssible classification rates for differential treatment outcomes.

96 We captured adverse treatment outcomes.

97 ed tuberculosis case notification and better treatment outcomes.

98 endently predicted unsuccessful tuberculosis treatment outcomes.

99 iver transplantation and chronic hepatitis C treatment outcomes.

100 limited durability represent a major gap in treatment outcomes.

101 promising results for improved tuberculosis treatment outcomes.

102 tients may be associated with antidepressant treatment outcomes.

103 of sudden unexpected death, and unfavourable treatment outcomes.

104 ) was unexpectedly associated with better TB treatment outcomes.

105 erapeutic regimen but who achieved different treatment outcomes.

106 mised phenotypes, we can potentially improve treatment outcomes.

107 y perspective leads to better predictions of treatment outcomes.

108 ve people in South Africa, adjusting for HIV treatment outcomes.

109 ology or have any significant effect on rCDI treatment outcomes.

110 est mortality risk are needed to improve HIV treatment outcomes.

111 clear operative field with likely beneficial treatment outcomes.

112 sonalized therapeutic approaches and improve treatment outcomes.

113 ades for predicting the risk of diseases and treatment outcomes.

114 egration-site distributions can be linked to treatment outcomes.

115 derstanding disease mechanisms and improving treatment outcomes.

116 ow patient-therapist relationships relate to treatment outcomes.

117 uded determining overall survival as well as treatment outcomes according to PD-L1 combined positive

118 in HIV care but is associated with poor HIV treatment outcomes after release.

119 Probiotics may improve treatment outcomes, although substantial heterogeneity i

120 Our aim in this review was to investigate treatment outcomes among PWID and patients on OST in com

121 Treatment outcomes among survivors of cancer diagnosed d

122 s pneumatic dilation on symptom severity and treatment outcomes among treatment-naive patients with a

123 ices, and directly observed therapy improved treatment outcome and compliance.

124 FP alone had a direct effect on tuberculosis treatment outcome and could greatly contribute to the go

125 The discordance between overall treatment outcome and low levels of clinical resistance

126 domized controlled phase III study comparing treatment outcome and toxicity between radiotherapy (RT)

127 and ocular motility disorders in relation to treatment outcomes and all synonyms.

128 induced response, which may modify radiation treatment outcomes and contribute to risk for radiation-

129 on risk factors for TB, associated with poor treatment outcomes and exacerbated by TB.

130 Perioperative data, technical information, treatment outcomes and follow-up results were collected.

131 leveraging them in the future for predicting treatment outcomes and informing clinical decision makin

132 and its comorbid conditions that complicate treatment outcomes and lead to organ dysfunction may hel

133 rities in human immunodeficiency virus (HIV) treatment outcomes and may be less likely to achieve dur

134 s nested within studies were used to examine treatment outcomes and moderators.

135 s to care is critically important to improve treatment outcomes and prevent amplification of drug res

136 Mental disorders can adversely affect HIV treatment outcomes and survival.

137 y also lead to discrepancies in the reported treatment outcomes and thus misinform the clinician or t

138 ine the role of p16 in HPV-related favorable treatment outcomes and to investigate the mechanisms by

139 The model is used to predict treatment outcomes and to suggest optimal treatment stra

140 es and be used to guide biomarker studies of treatment outcomes and/or genetic research.

141 Patient demographics, treatment outcome, and corresponding IVCM-MF performed a

142 wer of analyses of associations to genetics, treatment outcomes, and complications.

143 pecific treatment and vaccine-related costs, treatment outcomes, and disability weights to estimate t

144 eatment options, new insights for optimizing treatment outcomes, and emerging concepts of AF.

145 cts on tuberculosis (TB) natural history and treatment outcomes, and to assess the impact of these ef

146 specific immunoglobulins can help to predict treatment outcomes, and to differentiate transient desen

147 assess biologic tumor features decisive for treatment outcome are necessary.

148 Brain functions governing treatment outcome are not well characterized.

149 reatment ( approximately 35%); predictors of treatment outcome are therefore needed.

150 the implications of these discrepancies for treatment outcome are unknown.

151 Adequately powered studies comparing treatment outcomes are lacking.

152 sistant infections and their contribution to treatment outcomes are likely underestimated.

153 antiretroviral treatment era, neurosyphilis treatment outcomes are not different for PenG and APPG-P

154 SD patients treated with MMF, which reported treatment outcomes as Annualized Relapse Rate (ARR) or E

155 the outcome to fully explain away a specific treatment-outcome association, conditional on the measur

156 the outcome to fully explain away a specific treatment-outcome association, conditional on the measur

157 In subgroup analyses, better treatment outcomes at Months 3 and 12 were observed amon

158 and ANOVA were used to compare tuberculosis treatment outcomes between the two groups, and we estima

159 POAI has not been shown to improve treatment outcome, but can be used without detriment to

160 derlie this response variation could improve treatment outcomes by tailoring bleomycin dosages to eac

161 The results provide a spectrum of treatment outcomes - considering tumor targeting vs. ant

162 The study documents the end-of-treatment outcomes, culture-conversion rates, and seriou

163 Treatment outcome (cure, dropout, death, or development

164 Baseline TB severity, sputum conversion, and treatment outcomes (cure, failure, death, or loss to fol

165 me sequence data, resistance phenotypes, and treatment outcome data into model training will be cruci

166 gery (P<0.001) and in a lower risk of a poor treatment outcome (death or a low Kansas City Cardiomyop

167 Changes in treatment outcomes demonstrated small to moderate effect

168 Thus, treatment outcomes differ substantially among studies, r

169 y demonstrated that disease presentation and treatment outcomes differed between females and males.

170 hs with subsequent unsuccessful tuberculosis treatment outcome (failure/death during treatment or sub

171 neural networks contribute to variability in treatment outcomes for cocaine use disorder, and they id

172 otherwise remained concealed and to predict treatment outcomes for individual patients.

173 quinolone (FQ) resistance promise to improve treatment outcomes for individuals with multidrug-resist

174 ginal research investigations that evaluated treatment outcomes for OAL.

175 cancer has enormous potential for improving treatment outcomes for patients with breast cancer.See r

176 Treatment outcomes for sarcomatoid tumours have remained

177 uture research that might ultimately improve treatment outcomes for this common and debilitating tran

178 Real-world comparisons of biologic treatment outcomes for ulcerative colitis (UC) or Crohn'

179 elopmentally optimized approach to enhancing treatment outcomes for youths with anxiety disorders.

180 To review treatment outcomes from real-world data of patients with

181 developing TB and contributes to adverse TB treatment outcomes hence screening and integrated manage

182 -induced toxicity and potentially impacts RT treatment outcome in cancer patients through IR-induced

183 time to sputum culture conversion (tSCC) and treatment outcome in MDR-tuberculosis patients.

184 quinolones were correlated with unsuccessful treatment outcome in MDR-tuberculosis patients.

185 The association of MICs and treatment outcome in multidrug-resistant (MDR)-tuberculo

186 time to sputum culture conversion (SCC) and treatment outcome in patients with MDR-TB.

187 t patients and healthy controls and assessed treatment outcome in patients.

188 ition efficiency furthermore correlates with treatment outcome in some of these conditions.

189 elective serotonin reuptake inhibitor (SSRI) treatment outcome in two independent samples of patients

190 g ART below this threshold and its effect on treatment outcomes in a large South African cohort.

191 tremely low dosage and significantly improve treatment outcomes in acute kidney injury, acute liver i

192 and may have broader relevance for improving treatment outcomes in additional indications.

193 TSPAN5 SNPs were associated with acamprosate treatment outcomes in AUD patients.

194 ontal-striatal pathology could improve early treatment outcomes in AUD.

195 been the driving force behind the different treatment outcomes in both groups.

196 olsa Familia Programme (BFP) on tuberculosis treatment outcomes in Brazil.

197 nd they can improve other HIV prevention and treatment outcomes in certain settings in the short term

198 s specific circuit biomarkers for predicting treatment outcomes in childhood ADHD.

199 nd uniformity metrics did not correlate with treatment outcomes in children with DIPG in this study.

200 We estimated tuberculosis treatment outcomes in children younger than 5 years foll

201 ons, is one approach to improve tuberculosis treatment outcomes in children, especially malnourished

202 whether a single ketamine infusion improved treatment outcomes in cocaine-dependent adults engaged i

203 amine infusion improved a range of important treatment outcomes in cocaine-dependent adults engaged i

204 ith established chemotherapeutics to improve treatment outcomes in CRC patients.

205 rials of DBS in major depression, and modest treatment outcomes in dementia and epilepsy, are spurrin

206 nt characteristics, manifestation of TB, and treatment outcomes in different age groups were compared

207 SNPs were significantly associated with SSRI treatment outcomes in four independent MDD trials.

208 more frequent dosing is needed to improve TB treatment outcomes in India.

209 jor barrier for multiscale models to predict treatment outcomes in individual patients lies in their

210 can improve early prediction of neoadjuvant treatment outcomes in locally advanced breast cancer.

211 e levels were associated with antidepressant treatment outcomes in MDD.

212 with selective serotonin reuptake inhibitor treatment outcomes in patients with major depressive dis

213 is a prognostic biomarker for antidepressant treatment outcomes in patients with MDD.

214 tol, and explore relationships with clinical treatment outcomes in patients with pulmonary tuberculos

215 Calcium channel blockers (CCB) improve TB treatment outcomes in pre-clinical models, but their eff

216 ould also serve as biomarkers of unfavorable treatment outcomes in PTB is not known.

217 as a novel biomarker for predicting adverse treatment outcomes in PTB.

218 HCV treatment outcomes in PWID and patients on OST are simil

219 confirming the importance of MV integrity on treatment outcomes in RVD.

220 rties and HAP-radiation scheduling influence treatment outcomes in simulated tumours.

221 tential in treating T2D, due to its improved treatment outcomes in terms of extended release of exend

222 rsonalized therapy may improve adherence and treatment outcomes in the home.

223 ssociated with increased risk of unfavorable treatment outcomes in the validation cohort.

224 g evidence for the use of IgG1 in monitoring treatment outcomes in VL, and the first use of an IgG1-b

225 Treatment outcomes included event-free survival (EFS), o

226 treatment risk factors associated with worse treatment outcomes included obesity and presence of the

227 splantation (HSCT) had been done, as well as treatment outcomes, including complete remission, no res

228 cific functional network-based moderators of treatment outcome involving brain networks known to be a

229 antiretroviral treatment era, neurosyphilis treatment outcome is not different for PenG and APPG-P,

230 sures are indicators of target engagement or treatment outcome is not yet known.

231 A step towards improving treatment outcomes is in long-acting antiretrovirals.

232 The impact of early-onset cardiotoxicity on treatment outcomes is less well understood.

233 Improving treatment outcomes is nevertheless difficult, in part be

234 tro antimicrobial susceptibility and in vivo treatment outcomes is partially explained by microbes ad

235 Pitted against the hope for improving treatment outcomes is the threat of the rapid resistance

236 tients' expectations can dramatically affect treatment outcomes, less is known about the influence of

237 ycycline resistance is a misconception, with treatment outcome likely to be determined by other bacte

238 berculosis resistance mutations and M/XDR-TB treatment outcomes, limiting our current ability to expl

239 An estimated third of unfavourable treatment outcomes might be resolved with this dosing st

240 ables, and at least half of the variation in treatment outcomes occurs within zip codes.

241 s new formulation may be used to improve the treatment outcome of adenovirus-based cancer immunothera

242 butes to the incidence, clinical course, and treatment outcome of brain disorders.

243 ane exposure negatively impaired the overall treatment outcome of CAL gain (2.47 +/- 1.84 versus 1.03

244 However, when COM was used to rate the treatment outcome of each procedure, it appeared that a

245 d it to individually reproduce and elucidate treatment outcomes of 4 patients.

246 Purpose To report the final results on treatment outcomes of a randomized trial comparing conve

247 Kidney failure influences the treatment outcomes of abdominal aortic aneurysm (AAA).

248 stasis) in primary tumours could predict the treatment outcomes of adjuvant zoledronic acid.

249 This study compared the 12-month treatment outcomes of each drug in routine clinical prac

250 Identifying factors affecting the treatment outcomes of guided tissue regeneration (GTR) i

251 g regimens are not sufficient to improve the treatment outcomes of HAND.

252 ted through the same facility study; and (4) treatment outcomes of patients receiving primary-care-ba

253 Herein, we compare the 3-year treatment outcomes of the 2 in routine clinical practice

254 The successful treatment outcomes of this cohort show that regimens inc

255 arried out of the existing literature on the treatment outcomes of total neoadjuvant therapy (TNT) on

256 = 0.448) and patients' assessments of their treatment outcomes (P = 0.503).

257 ocaine in the past 28 days, as measured with treatment outcomes profiles and urine drug screening.

258 prognostic models are inadequate-often using treatment outcomes rather than survival, stratifying by

259 1 and BRCA2 germline mutation status affects treatment outcome remains elusive.

260 istory of mental illness, mortality, and HIV treatment outcomes (retention in care with viral load su

261 We describe the treatment outcomes, safety, and tolerability of bedaquil

262 We describe treatment outcomes, safety, and tolerability of bedaquil

263 nd shoulder functional status (Breast Cancer Treatment Outcome Scale); body image and sexuality (Body

264 ducing the RUTF dose in a routine program on treatment outcomes should be evaluated before scaling up

265 -acting properties have potential to improve treatment outcomes substantially for people living with

266 ls of non-adherence described did not impact treatment outcomes, suggesting forgiveness to non-adhere

267 Nonadherence described did not impact treatment outcomes, suggesting forgiveness to nonadheren

268 amine transporter rescued antipsychotic drug treatment outcomes, supporting the hypothesis that the d

269 atment immune response is more predictive of treatment outcome than immune features in paired baselin

270 Children and adolescents have poorer HIV treatment outcomes than adults.

271 berculosis and adversely affect tuberculosis treatment outcomes, the global burden of diabetes in the

272 Given the need to improve treatment outcomes, this study examined the efficacy of

273 aseline blood tests correlated with week 117 treatment outcomes, this study might aid in optimal pati

274 avioral interventions to enhance longer-term treatment outcomes through a synergistic effect.

275 chanistic studies of brain cancer and better treatment outcomes through precision oncology.

276 insulin (OI338) was shown to provide similar treatment outcomes to insulin glargine in a phase 2a cli

277 amydia, with preliminary evidence of similar treatment outcomes to those in traditional services.

278 le regression, and unsuccessful tuberculosis treatment outcome (treatment failure, tuberculosis recur

279 peak systolic hemodynamics of the real post-treatment outcome using patient-specific MRI measured bo

280 d mortality in immunosuppressed patients and treatment outcomes using oral antifungal triazoles remai

281 However, treatment outcome varies greatly among patients.

282 After resective therapy, a successful treatment outcome was defined as peri-implant health wit

283 Successful treatment outcome was observed in 83.5% (132/158) of MDR

284 A favorable end-of-treatment outcome was reported in 86 participants (87.8%

285 Treatment outcomes were analyzed by logistic or Cox regr

286 Treatment outcomes were available in 58 cases.

287 Treatment outcomes were compared between management with

288 Treatment outcomes were compared between participants re

289 registry of nAMD treatment outcomes were considered to have suspended tre

290 Case definitions of possible treatment outcomes were discussed, and a flowchart was c

291 Three possible treatment outcomes were identified after resective treat

292 Successful end-of-treatment outcomes were reported in 49(70%) patients.

293 ciated with an increased risk for adverse TB treatment outcomes, while comorbid, poorly controlled di

294 M. tuberculosis isolates affects disease and treatment outcomes will enable the development of more e

295 fore starting treatment, allowing to predict treatment outcome with a predictive value of 93.8% when

296 el biomarker that will significantly improve treatment outcome with ATR and CHK1 inhibitors.

297 meaningful impact of baseline SRF status on treatment outcomes with IAI was demonstrated, indicating

298 sistant (RR) TB, a proxy for MDR-TB, and the treatment outcomes with standard and shortened regimens

299 gy may have value as an objective measure of treatment outcomes within outpatient methadone clinics.

300 This may already be producing successful treatment outcomes without our knowing that transmitter